Video
How genomic testing can address accuracy issues with PSA screening and monitoring
Author(s):
Video Player is loading.
Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how the precision of genomic testing data can alleviate the accuracy issues associated with PSA testing for screening and monitoring prostate cancer.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Closing Thoughts on Urology Practice Management and Treatment of Advanced Prostate Cancer
Overcoming Staffing Challenges and Turnover in Urology Practices
Scheduling and Administering Leuprolide: Key Challenges and Practical Solutions
The Impact of Telehealth on Treatment Selection in Advanced Prostate Cancer
Complementary use of mpMRI and genomic testing in prostate cancer
Dr. Helfand on how genomic testing provides real-time status of prostate tumor
Dr. Helfand on the increasing role of genomic testing in prostate cancer
Around the Practice July 21, 2021: Bladder Cancer Cases
Genetic, Genomic Testing in Heavily Treated, Metastatic Castrate-Resistant Prostate Cancer
Genetic, Genomic Testing in Newly Diagnosed, High-Grade, High-Risk Prostate Cancer
Related Content
